Filled Insulin Pen - Complete Clinical Detail

What Is a Filled Insulin Pen?

• Goldman-Cecil Medicine: "Insulin pen devices can be disposable (i.e., discarded when the insulin is used up) or contain cartridges that can be changed."
• Textbook of Family Medicine 9e: "Multiple daily injections should be initiated and maintained with the use of insulin pens rather than syringes and vials."

Types of Filled Insulin Pens

1. Disposable Prefilled Pens

• Come factory-filled with a fixed amount of insulin (typically 300 units / 3 mL).
• Discarded entirely once insulin is used up or after a specified number of days (usually 28 days after first use).
• No cartridge changes needed.
• Most common in clinical practice.

2. Reusable Pens with Replaceable Cartridges

• The pen body is reused; only the 3 mL insulin cartridge is replaced when empty.
• More economical in the long run; less plastic waste.

3. Smart / Connected Insulin Pens

• Digital pens that automatically log the time and dose of each injection.
• Data is transmitted via Bluetooth/internet to a smartphone app.
• App may calculate correction doses, track patterns, and integrate with CGM data.
• Can be a full pen unit or a smart cap that attaches to existing pens.

Parts of an Insulin Pen

Insulin Formulations Available in Prefilled Pens

Important: Higher concentration pens (U200, U300, U500) contain more insulin per mL. The dose window still displays units - not volume - to prevent dosing errors.

Bioavailability / Pharmacokinetic Summary

Advantages Over Vials and Syringes

• Accuracy: More accurate than syringes for doses ≤5 units - important for children and adolescents.
• Easy to teach: Clinicians can teach pen use in under 3 minutes on average.
• Less needle phobia: 30-31 gauge short needles are used; the needle does not need to pierce a rubber vial stopper (which blunts the tip and increases pain).
• Portability: Easily carried in a pocket or purse; no vials or separate syringes needed.
• No refrigeration needed (in use): Open pens can be stored at room temperature (68-72°F / 20-22°C) for up to 28 days.
• Adherence: Studies consistently show patients prefer pens over vials and syringes.
• Assists special populations: Older patients with visual impairments, tremors, or impaired motor skills find pens easier to use.

How to Use a Prefilled Insulin Pen (Step-by-Step)

Preparation

1. Wash hands thoroughly.
2. Check the pen label - confirm insulin type, concentration, and expiration date.
3. If using cloudy/suspension insulin (NPH, premixed), roll the pen gently between palms 10 times, then tip end-to-end 10 times to mix. Do not shake.
4. Remove the pen cap.
5. Attach a new needle: remove the paper tab, screw the needle straight onto the pen.
6. Remove the outer and inner needle caps; keep the outer cap for safe disposal.

Prime the Pen (Air Shot)

1. Dial 2 units.
2. Hold pen with needle pointing up; tap to bring air bubbles to the top.
3. Press the injection button - a drop of insulin should appear at the needle tip. This confirms the pen is working and clears any air.
4. If no drop appears, repeat up to 3 times. If still no drop, use a new pen.

Select and Inject the Dose

1. Dial the prescribed dose.
2. Choose an injection site (abdomen, thigh, upper arm, or buttock). Rotate sites within the same region.
3. Clean the site with an alcohol swab; let it dry.
4. Pinch the skin (if needed for thin individuals) and insert the needle at 90° (or 45° for very thin patients).
5. Press the injection button fully and hold for 6-10 seconds to ensure complete delivery.
6. Remove the needle; do not rub the site.

After Injection

1. Replace the outer needle cap (without recapping by hand - use the cap on a surface), then unscrew and discard the needle into a sharps container.
2. Replace the pen cap.
3. Document the dose and time.

Injection Sites

• Abdomen (fastest absorption) - avoid 2 inches around the navel
• Upper thigh (outer surface)
• Upper arm (outer/posterior surface)
• Buttock (upper outer quadrant)

Storage

• Never freeze; do not expose to direct sunlight or high heat.
• Write the date of first use on the pen.

Safety Points

• Never share a pen between patients, even with a new needle - risk of bloodborne pathogen transmission.
• Always use a new needle for each injection to prevent lipohypertrophy, infection, and dosing inaccuracy (blunt needles deliver less reliably).
• Prescribe by full brand name including concentration (e.g., "Toujeo U300" not just "glargine") to avoid dangerous dosing mix-ups between U100 and U300/U200 products.
• For U500 regular insulin, the disposable pen dispenses in 5-unit increments to reduce conversion errors.
• Emergency fallback: Patients on insulin pumps should always be trained to use pen/syringe insulin as backup in case of pump failure.

Note on the name: "Galgrin" is most likely a regional/local brand name or a phonetic spelling of Insulin Glargine (pronounced GLAR-jin or GLAR-geen). "Galgrin" is not listed among the major international brand names (Lantus, Basaglar, Toujeo, Semglee, Rezvoglar), but it is used as a brand name in some countries (e.g., India). The drug itself is Insulin Glargine - a long-acting basal insulin analog.

Insulin Glargine (Galgrin) - Complete Detail

Classification & Basic Identity

Molecular Structure - How It Is Modified

1. B-chain: Two arginine residues added to the C-terminus (positions B31 and B32)
2. A-chain: Asparagine at position A21 replaced with glycine

• Shift the isoelectric point from pH 5.4 to pH 6.7 (closer to neutral)
• Make glargine soluble at acidic pH (4.0) - the injectable solution is clear and acidic
• Cause precipitation at neutral body pH after subcutaneous injection, forming a crystalline depot
• Individual insulin molecules slowly dissolve from this depot, providing a slow, steady release

Mechanism of Action

• After SC injection, glargine precipitates at the neutral tissue pH, forming a subcutaneous microcrystalline depot.
• Insulin monomers slowly dissolve from this depot into the circulation, providing a flat, peakless plasma concentration profile.
• Once absorbed, it binds to the insulin receptor on target cells (liver, muscle, adipose), activating glucose uptake, glycogen synthesis, and inhibiting gluconeogenesis - same mechanism as native insulin.
• Glargine's interaction with the insulin receptor is similar to native insulin with no increase in mitogenic activity in vitro.
• It has 6-7x greater binding to IGF-1 receptor than native insulin - clinical significance is still unclear.

Pharmacokinetics

From Lippincott Illustrated Reviews - Pharmacology: "It has a slower onset than NPH insulin and a flat, prolonged hypoglycemic effect with no peak."

Available Concentrations

• U300 (Toujeo) has a longer duration and even flatter profile than U100 glargine due to a smaller volume of injection creating a more compact depot.

Indications

• Type 1 Diabetes Mellitus - as basal insulin (must always be combined with a rapid/short-acting insulin for meals)
• Type 2 Diabetes Mellitus - when oral agents are insufficient; used as basal insulin
• Gestational diabetes / Pregnancy - Creasy & Resnik's Maternal-Fetal Medicine notes glargine can provide stable basal insulin release throughout the 24-hour day; safety data in pregnancy is available

Dosing

• Typical starting dose (T2DM): 10 units SC once daily, or 0.1-0.2 units/kg/day
• Timing: Can be administered at any time of day (morning or bedtime) with equivalent efficacy - does not need to be fixed to a specific time
• Dose titration: Increase by 2 units every 3 days (or as directed) to reach fasting glucose target
• Split dosing: Very insulin-sensitive patients (<20 units/day) or highly insulin-resistant patients may benefit from twice-daily dosing
• Does not accumulate after multiple injections

Administration Rules - Critical Points

1. Do NOT mix with other insulins - the acidic pH (4.0) alters the pharmacodynamics of neutral-pH insulins; a separate syringe must be used.
2. Subcutaneous injection only - never IV
3. Do NOT shake - roll gently if needed (though glargine is a clear solution, not a suspension)
4. Site rotation - abdomen, thigh, upper arm
5. Absorption is site-independent (unlike regular insulin, which is fastest from the abdomen)

Comparison with Other Long-Acting Insulins

From Textbook of Family Medicine 9e: "Glargine provides glycemic control that is at least comparable with NPH in adults, adolescents, and children."

Advantages Over NPH Insulin

• Peakless profile reduces nocturnal and between-meal hypoglycemia
• More predictable absorption
• Lower immunogenicity in animal studies
• Can be given at any time of day (NPH timing matters more)
• Lower risk of overnight hypoglycemia - confirmed in clinical trials (Goodman & Gilman's)
• Glargine biosimilar formulations are now available, improving cost access

Side Effects

Contraindications / Precautions

• Hypoglycemia episode (active) - do not inject
• Diabetic ketoacidosis - requires rapid-acting IV insulin, not long-acting SC glargine
• Cannot be mixed with other insulins in same syringe
• Do not use IV
• Adjust dose in renal or hepatic impairment (reduced insulin clearance)
• Pregnancy: generally considered safe; use with monitoring

Storage

• Protect from light and freezing
• Discard if frozen or if particles/cloudiness appear (glargine should always be clear and colorless)

MCQ Point (from Lippincott Illustrated Reviews)

Q: Which statement is correct regarding insulin glargine? A: It is a "peakless" insulin. ✓ (It is used for basal - not postprandial - control; its prolonged action is due to precipitation at neutral pH, not protein binding like detemir)